Veozah vs Lynkuet: how the two non-hormonal hot flash drugs compare

How they work: NK3 vs dual NK1/NK3

Both drugs act on KNDy neurons in the hypothalamus, the brain's temperature-control center, where falling estrogen leaves neurokinin signaling overactive and triggers hot flashes. Veozah is a neurokinin 3 (NK3) receptor antagonist: it blocks that one pathway. Lynkuet is the first and only drug that blocks two, neurokinin 1 (NK1) and neurokinin 3 (NK3).

The extra NK1 blockade is the reason Lynkuet is positioned around sleep as well as hot flashes: NK1 signaling is involved in sleep and mood, and Lynkuet's trials tracked sleep disturbance as a formal outcome. Whether blocking two receptors relieves hot flashes better than blocking one is unproven without a head-to-head trial. Winner on breadth of mechanism: Lynkuet. Winner on the mechanism being tested longest in the real world: Veozah.

Approval and track record

Veozah, made by Astellas, was FDA-approved on May 12, 2023, the first drug in this non-hormonal class. That gives it more than two years of real-world use and post-marketing safety data, which is how its rare liver-injury signal was caught and acted on.

Lynkuet, made by Bayer, was FDA-approved on October 24, 2025. It is the newer option with a cleaner monitoring profile so far, but far less real-world exposure, so uncommon risks that only show up at scale may not be visible yet. Winner on track record: Veozah. Winner on being the newest option built on lessons from the first: Lynkuet.

What the trials showed

Veozah's SKYLIGHT 1 and 2 trials showed roughly a 50 percent or greater cut in hot flash frequency by week 4 (versus about 30 percent on placebo) and about a 65 percent reduction by week 12 (versus about 45 percent on placebo).

Lynkuet's OASIS program (OASIS 1, 2, and 3) showed a similar magnitude of relief plus a measured improvement in sleep disturbance and menopause-related quality of life. In the year-long OASIS 3 trial, women averaging about 6.7 moderate to severe hot flashes a day were down to roughly 1.3 a day at 12 weeks, versus about 3.3 on placebo. These are separate trials against placebo, not against each other, so the percentages are not directly comparable. Winner on relief of hot flashes alone: too close to call without a head-to-head. Winner when sleep is also a target: Lynkuet, on the strength of its trial design.

The liver-injury question

This is the sharpest practical difference. On December 16, 2024, the FDA added a boxed warning, its most prominent warning, to Veozah for rare but serious liver injury, after a post-marketing case. Veozah now calls for a liver blood test before starting, then monthly for the first three months, and again at months 6 and 9.

Lynkuet's label carries a hepatic transaminase warning but no boxed warning. It calls for a baseline liver test (and you do not start if levels are already at or above twice the upper limit of normal), then a single follow-up at 3 months. In its two 12-week controlled trials, no Lynkuet-treated woman had liver enzyme elevations meeting the criteria for liver injury, which is why reviewers concluded a boxed warning was not warranted at this time. The caveat: Veozah also looked reassuring at first, and its signal appeared only after wide real-world use. Winner on lighter monitoring and current liver-safety profile: Lynkuet, with the honest asterisk that it has far less real-world data.

Side effects and the daily experience

Veozah's most common side effects in trials were abdominal pain, diarrhea, insomnia, back pain, and elevated liver enzymes. It is taken once a day at any time.

Lynkuet is taken as two capsules (120 mg) once daily at bedtime, partly because its most notable side effects are nervous-system ones: somnolence, fatigue, dizziness, and related effects occurred in about 11.9 percent of women versus 3.5 percent on placebo, along with headache. Bedtime dosing turns that sedation into a potential sleep aid rather than a daytime problem. Winner if you want daytime dosing and less sedation: Veozah. Winner if bedtime sedation and a sleep benefit are welcome: Lynkuet.

Cost and access

Both are brand-name drugs with no generic, and both are expensive without coverage. Veozah's list price was about $566 for a 30-day supply as of early 2025; Lynkuet's list price is about $625 a month. Both makers run commercial copay programs (Veozah advertises a first month as low as $0 and refills as low as $30; Lynkuet advertises as low as $25 a month for eligible commercially insured patients), and both may require prior authorization or step therapy.

Because Veozah has been covered longer, more plans have an established path for it; Lynkuet's coverage is still expanding. Winner on established insurance pathways: Veozah, narrowly. Winner on sticker price and copay card: close to a tie. For anyone paying cash, neither is cheap.

Who each one suits

There is no overall winner, because the right pick depends on what you are solving for.

• Lean Veozah if you want the option with the longest track record, prefer daytime dosing, do not want bedtime sedation, and do not mind the closer early liver monitoring.
• Lean Lynkuet if disrupted sleep is a big part of your symptoms, you would rather have lighter liver monitoring and no boxed warning, and you are comfortable being on a newer drug.
• Either way, hormone therapy is still generally the most effective treatment for hot flashes for women who can take it; these two are the leading choices when hormones are not an option or not wanted.